publication date: May. 27, 2016

ASCO Cervical Cancer Guideline 

Addresses Global Disparities 


The American Society of Clinical Oncology issued its first clinical practice guideline for invasive cervical cancer.

The guideline provides evidence-based recommendations for four tiers based on available resources for cervical cancer screening and treatment: basic, limited, enhanced and maximal. For each setting, and for each stage of cervical cancer, the guideline recommends optimal therapy and palliative care. The guideline was published in the Journal of Global Oncology and was endorsed by the Society of Gynecologic Oncology.

“Even though cervical cancer is largely preventable, a quarter of a million women die of this disease every year globally. The vast majority of those deaths occur in less developed regions of the world, such as South-East Asia, the Western Pacific, India and Africa,” said Linus Chuang, co-chair of the ASCO Expert Panel that developed the guideline, and a gynecologic oncologist and a professor of obstetrics, gynecology and reproductive science at the Mount Sinai Icahn School of Medicine. “In those regions, access to pathology services, skilled surgeons, radiation machines, brachytherapy, chemotherapy and palliative care may all be constrained.”

According to the guideline, in basic settings where patients cannot be treated with radiation therapy, extrafascial hysterectomy either alone or after neoadjuvant chemotherapy may be an option for women with stage IA1 to IVA cervical cancer.

Concurrent radiotherapy and chemotherapy is standard in enhanced and maximal settings for women with stage IB to IVA disease. The panel stressed the addition of low-dose chemotherapy during radiotherapy, but not at the cost of delaying … Continue reading 42-21 ASCO Cervical Cancer Guideline Addresses Global Disparities

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.